Recombinant human IFN-α was the first immunotherapy to undergo substantial clinical development in HCC, due to the extensive experience gained in the treatment of chronic viral hepatitis as well as to its anti-angiogenic and immunostimolatory proprieties [47]. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.